Authors: Alice Weatherston
Newly developed methods to analyze the brain and spinal fluid may help to diagnose Alzheimer’s disease, a new European study has revealed. The discovery could also have implications for drug choice and patient inclusion in clinical trials for new therapies.
The group, which is made up of seven memory clinics and led by researchers at Karolinska Institute, compared amyloid-PET measurements in the brain with amyloid-β42 in the spinal fluid to evaluate potential associations. The data was collected from 230 patients in total that had been referred for memory disorders and had been diagnosed with mild cognitive impairment (MCI), Alzheimer’s disease and other types of dementia. There was also a small group of healthy individuals included as controls to the investigation.